Citadel Advisors LLC lessened its position in AtriCure, Inc. (NASDAQ:ATRC) by 34.9% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 25,857 shares of the medical device company’s stock after selling 13,835 shares during the period. Citadel Advisors LLC owned approximately 0.08% of AtriCure worth $627,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in ATRC. Wells Fargo & Company MN grew its position in AtriCure by 131.9% in the 1st quarter. Wells Fargo & Company MN now owns 112,006 shares of the medical device company’s stock valued at $2,145,000 after buying an additional 63,711 shares in the last quarter. Bank of New York Mellon Corp grew its position in AtriCure by 24.2% in the 1st quarter. Bank of New York Mellon Corp now owns 179,586 shares of the medical device company’s stock valued at $3,439,000 after buying an additional 35,013 shares in the last quarter. Swiss National Bank grew its position in AtriCure by 7.0% in the 1st quarter. Swiss National Bank now owns 54,700 shares of the medical device company’s stock valued at $1,048,000 after buying an additional 3,600 shares in the last quarter. Parametric Portfolio Associates LLC grew its position in AtriCure by 11.2% in the 1st quarter. Parametric Portfolio Associates LLC now owns 34,622 shares of the medical device company’s stock valued at $663,000 after buying an additional 3,488 shares in the last quarter. Finally, American International Group Inc. grew its position in AtriCure by 7.0% in the 1st quarter. American International Group Inc. now owns 19,346 shares of the medical device company’s stock valued at $370,000 after buying an additional 1,273 shares in the last quarter. 82.11% of the stock is currently owned by institutional investors and hedge funds.
WARNING: This report was first published by BBNS and is the sole property of of BBNS. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://baseballnewssource.com/markets/citadel-advisors-llc-reduces-position-in-atricure-inc-atrc/1698290.html.
Several equities analysts have recently weighed in on the stock. Stifel Nicolaus restated a “buy” rating and set a $25.00 price objective on shares of AtriCure in a research report on Sunday, July 30th. BidaskClub lowered shares of AtriCure from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. Canaccord Genuity reiterated a “buy” rating and issued a $28.00 target price on shares of AtriCure in a report on Monday, October 9th. Zacks Investment Research upgraded shares of AtriCure from a “sell” rating to a “hold” rating in a report on Monday, October 2nd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $26.00 target price (up from $25.00) on shares of AtriCure in a report on Friday, July 28th. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $25.83.
AtriCure, Inc. (NASDAQ ATRC) opened at 22.61 on Tuesday. AtriCure, Inc. has a 52-week low of $14.78 and a 52-week high of $25.18. The company’s market cap is $776.29 million. The stock has a 50 day moving average of $21.85 and a 200-day moving average of $21.95.
AtriCure (NASDAQ:ATRC) last released its quarterly earnings data on Thursday, July 27th. The medical device company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.05. AtriCure had a negative return on equity of 19.56% and a negative net margin of 19.56%. The company had revenue of $45.23 million for the quarter, compared to analyst estimates of $44.15 million. During the same period in the previous year, the company posted ($0.26) EPS. The firm’s revenue for the quarter was up 14.0% compared to the same quarter last year. On average, analysts forecast that AtriCure, Inc. will post ($0.95) EPS for the current year.
In related news, Director Elizabeth D. Krell sold 10,000 shares of the business’s stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $22.40, for a total transaction of $224,000.00. Following the completion of the transaction, the director now directly owns 29,967 shares in the company, valued at $671,260.80. The transaction was disclosed in a document filed with the SEC, which is available through this link. 10.00% of the stock is owned by insiders.
AtriCure Company Profile
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with our FREE daily email newsletter.